{"id":"addition-of-oral-metolazone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metolazone blocks the Na-Cl cotransporter in the distal convoluted tubule of the nephron, preventing reabsorption of sodium and chloride and thereby increasing urine output. This reduces blood volume and intravascular fluid, lowering blood pressure and reducing edema. It is particularly effective when combined with loop diuretics in resistant edema or heart failure due to its synergistic action at different sites of the nephron.","oneSentence":"Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:40.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with renal disease"}]},"trialDetails":[{"nctId":"NCT07372040","phase":"PHASE2","title":"Add-on Diuretics in Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Acute Decompensated Heart Failure","enrollment":66},{"nctId":"NCT07199088","phase":"NA","title":"Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2025-10-11","conditions":"Acute Decompensated Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic","enrollment":320},{"nctId":"NCT06166654","phase":"PHASE4","title":"Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload","status":"RECRUITING","sponsor":"Johannes Grand","startDate":"2024-09-05","conditions":"Acute Heart Failure","enrollment":939},{"nctId":"NCT06414759","phase":"PHASE4","title":"Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Acute Decompensated Heart Failure, Volume Overload, Edema","enrollment":110},{"nctId":"NCT05904808","phase":"PHASE4","title":"The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2023-04-19","conditions":"Chronic Heart Failure, Diuretics Drug Reactions, Congestive Heart Failure","enrollment":42},{"nctId":"NCT06273397","phase":"NA","title":"Acetazolamide or Metolazone in Acute Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Clinica Alemana de Santiago","startDate":"2024-05-01","conditions":"Heart Failure Acute, Decompensated Heart Failure","enrollment":1050},{"nctId":"NCT06218199","phase":"PHASE4","title":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","status":"RECRUITING","sponsor":"Heart Center Research, LLC","startDate":"2021-07-08","conditions":"Heart Failure, Congestive","enrollment":80},{"nctId":"NCT03746002","phase":"PHASE4","title":"Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2019-01-01","conditions":"Fluid Overload, Heart Failure Acute","enrollment":3},{"nctId":"NCT04907123","phase":"PHASE3","title":"Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2021-10","conditions":"Heart Failure","enrollment":198},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03574857","phase":"PHASE4","title":"Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-06-01","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure Acute","enrollment":5},{"nctId":"NCT04163588","phase":"PHASE3","title":"Sequential Nephron Blockade in Acute Heart Failure","status":"UNKNOWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2019-10-01","conditions":"Acute Heart Failure","enrollment":310},{"nctId":"NCT02606253","phase":"PHASE4","title":"Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-02","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT04062760","phase":"PHASE4","title":"Safety and Efficacy of Early, seQUential Oral dIuretic Nephron blockAde In Acute Heart Failure","status":"UNKNOWN","sponsor":"University of Parma","startDate":"2019-12-01","conditions":"Acute Heart Failure","enrollment":206},{"nctId":"NCT02646540","phase":"PHASE1","title":"AiDing Diuresis wIth Tolvaptan (ADD-IT)","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Cardiomyopathy, Congestive Heart Failure","enrollment":14},{"nctId":"NCT00904488","phase":"PHASE4","title":"Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-10","conditions":"Acute Decompensated Heart Failure","enrollment":11},{"nctId":"NCT01921829","phase":"PHASE4","title":"Protocolized Diuretic Strategy in Cardiorenal Failure","status":"TERMINATED","sponsor":"Kelly V. Liang, MD","startDate":"2013-11","conditions":"Cardiac Failure, Renal Failure, Kidney Failure","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zaroxolyn"],"phase":"marketed","status":"active","brandName":"Addition of oral Metolazone","genericName":"Addition of oral Metolazone","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}